Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Read More…
Industry, Sector and Symbol
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Phone513-762-6690
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.78 billion
Profitability
Miscellaneous
Employees15,707
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable
Chemed (NYSE:CHE) Frequently Asked Questions
What is Chemed's stock symbol?
Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."
How often does Chemed pay dividends? What is the dividend yield for Chemed?
Chemed declared a quarterly dividend on Friday, August 2nd. Shareholders of record on Monday, August 12th will be given a dividend of $0.32 per share on Tuesday, September 3rd. This represents a $1.28 annualized dividend and a yield of 0.31%. The ex-dividend date is Friday, August 9th. This is an increase from Chemed's previous quarterly dividend of $0.30. View Chemed's Dividend History.
How will Chemed's stock buyback program work?
Chemed announced that its Board of Directors has authorized a stock buyback program on Wednesday, March 7th 2018, which allows the company to buyback $150,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company's board believes its shares are undervalued.
How were Chemed's earnings last quarter?
Chemed Co. (NYSE:CHE) announced its quarterly earnings data on Thursday, July, 25th. The company reported $3.36 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.09 by $0.27. The firm earned $473.60 million during the quarter, compared to analyst estimates of $471.72 million. Chemed had a net margin of 10.94% and a return on equity of 35.63%. Chemed's quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.81 EPS. View Chemed's Earnings History.
When is Chemed's next earnings date?
How can I listen to Chemed's earnings call?
Chemed will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Chemed issued on next quarter's earnings?
Chemed issued an update on its FY19 earnings guidance on Monday, August, 5th. The company provided earnings per share (EPS) guidance of $13.65-13.85 for the period, compared to the Thomson Reuters consensus estimate of $13.22.
What price target have analysts set for CHE?
3 equities research analysts have issued twelve-month target prices for Chemed's shares. Their predictions range from $405.00 to $500.00. On average, they expect Chemed's stock price to reach $445.00 in the next year. This suggests a possible upside of 7.1% from the stock's current price. View Analyst Price Targets for Chemed.
What is the consensus analysts' recommendation for Chemed?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chemed.
Has Chemed been receiving favorable news coverage?
Media coverage about CHE stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chemed earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Chemed.
Are investors shorting Chemed?
Chemed saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 265,800 shares, a decrease of 9.8% from the August 30th total of 294,600 shares. Based on an average daily volume of 122,200 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.7% of the company's shares are sold short. View Chemed's Current Options Chain.
Who are some of Chemed's key competitors?
Some companies that are related to Chemed include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), R1 RCM (RCM), The Providence Service (PRSC), Tivity Health (TVTY), BioScrip (BIOS), Cross Country Healthcare (CCRN), Interpace Diagnostics Group (IDXG) and Bio-Reference Laboratories (BRLI).
What other stocks do shareholders of Chemed own?
Who are Chemed's key executives?
Chemed's management team includes the folowing people:
- Mr. Kevin J. McNamara, CEO, Pres & Director (Age 65)
- Mr. David P. Williams, Exec. VP & CFO (Age 58)
- Ms. Naomi C. Dallob, VP, Chief Legal Officer & Sec. (Age 65)
- Mr. Spencer S. Lee, Exec. VP (Age 63)
- Mr. Nicholas Michael Westfall, Exec. VP (Age 40)
Who are Chemed's major shareholders?
Chemed's stock is owned by a number of of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (2.34%), Boston Trust Walden Corp (0.74%), Robeco Institutional Asset Management B.V. (0.27%), Envestnet Asset Management Inc. (0.21%), Nisa Investment Advisors LLC (0.07%) and Decatur Capital Management Inc. (0.06%). Company insiders that own Chemed stock include David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs. View Institutional Ownership Trends for Chemed.
Which institutional investors are selling Chemed stock?
CHE stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., TrimTabs Asset Management LLC, Brookstone Capital Management, Hanson & Doremus Investment Management, Pacer Advisors Inc., Delta Capital Management LLC, Capital Insight Partners LLC and Crossmark Global Holdings Inc.. Company insiders that have sold Chemed company stock in the last year include David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Spencer S Lee, Thomas P Rice and Walter L Krebs. View Insider Buying and Selling for Chemed.
Which institutional investors are buying Chemed stock?
CHE stock was bought by a variety of institutional investors in the last quarter, including Decatur Capital Management Inc., Boston Trust Walden Corp, Robeco Institutional Asset Management B.V., Nisa Investment Advisors LLC, Campbell & CO Investment Adviser LLC, State of Alaska Department of Revenue, Iron Financial LLC and Sabal Trust CO. Company insiders that have bought Chemed stock in the last two years include Donald E Saunders and George J Walsh III. View Insider Buying and Selling for Chemed.
How do I buy shares of Chemed?
Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Chemed's stock price today?
One share of CHE stock can currently be purchased for approximately $415.51.
How big of a company is Chemed?
Chemed has a market capitalization of $6.62 billion and generates $1.78 billion in revenue each year. The company earns $205.54 million in net income (profit) each year or $11.93 on an earnings per share basis. Chemed employs 15,707 workers across the globe.View Additional Information About Chemed.
What is Chemed's official website?
How can I contact Chemed?
Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.
MarketBeat Community Rating for Chemed (NYSE CHE)
MarketBeat's community ratings are surveys of what our community members think about Chemed and other stocks. Vote "Outperform" if you believe CHE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHE will underperform the S&P 500 over the long term. You may vote once every thirty days.
